MedTrace Logo

Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

NCT00230763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2021-02-18

No results posted yet for this study

Summary

To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).

Conditions

Interventions

PROCEDURE

GSS questionnaire

D0, D30 and D84

PROCEDURE

IOP

D0, D30 and D84

DRUG

LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION

in the evening during 84 days

PROCEDURE

Visual acuity

D0 and D84

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230763 on ClinicalTrials.gov